Sort
82,697 grants matching “vaccine development”
Bifidobacterium infantis supplementation in early life to improve immunity in infants exposed to HIV: a randomized, placebo-controlled, double-blind trial
$760,095Heather Beryl Jaspan · Seattle Children'S Hospital · R01 · FY2024 · HD
Tfh dysfunction in HIV and Aging
$760,092Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2021 · AG
Refinement of an autodissemination station for control of mosquito vectors
$760,087Michael Gilbert Banfield · Banfieldbio Inc. · R44 · FY2015 · AI
Targeting the HIV-1 reservoir with a combination of an IDLV-SIVGag therapeutic vaccine and Fc-engineered bnAbs
$760,086Maria Blasi · Duke University · R56 · FY2020 · AI
Rocky Mountain Spotted Fever Vaccine Development
$760,028Roman R. Ganta · Kansas State University · R01 · FY2021 · AI
Factors Influencing Oral Transmission of SIV
$760,001Donald L Sodora · Seattle Biomedical Research Institute · R01 · FY2007 · DE
IHBEM: Data-driven integration of behavior change interventions into epidemiological models using equation learning
$760,000Osman Y Ozaltin · North Carolina State University · · FY2023 · MPS
Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS)
$759,945Sabra L Klein · Johns Hopkins University · U54 · FY2024 · CA
Mechanisms of Norovirus Protective Immunity
$759,938Ralph S Baric · Univ Of North Carolina Chapel Hill · R56 · FY2014 · AI
Infant Immunoprophylaxis against a Primate Lentivirus
$759,922Ruth Margrit Ruprecht · Dana-Farber Cancer Inst · R37 · FY2012 · AI
IMPDH inhibitors for the treatment of Cryptosporidium infections
$759,898Gregory D Cuny · University Of Houston · R01 · FY2017 · AI
Preventing HIV Transmission by Recently-Infected Drug Users
$759,825Samuel R Friedman · National Development And Research Institutes, Inc. · DP1 · FY2016 · DA
Genomic approaches to define hookworm population diversity and deworming drug response
$759,777Michael Cappello · Yale University · R01 · FY2024 · AI
HIV-1 vaccine-elicited antibodies target envelope glycans
$759,765Kevin O Saunders · Duke University · R01 · FY2017 · AI
Spontaneous and Induced B cell and T cell responses in Alzheimer's Disease
$759,744Marco Colonna · Washington University · R01 · FY2025 · AG
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses
$759,731Lanying Du · Georgia State University · R01 · FY2022 · AI
B cell memory in human food allergy
$759,710Maria A Curotto De Lafaille · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · AI
Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions
$759,667Harel Dahari · Loyola University Chicago · R01 · FY2022 · AI
Innate and early B cell responses to V. cholerae
$759,607Jason B Harris · Massachusetts General Hospital · R01 · FY2017 · AI
Novel delivery platform and antigen design for an effective COVID-19 vaccine
$759,584Suresh K Mittal · Purdue University · R01 · FY2025 · AI
Immunostimulatory DNA Priming of Lung Innate Immunity
$759,577Dynavax Technologies Corporation · U01 · FY2004 · AI
NIDA Clinical Trials Network: Greater New York Node
$759,467John P Rotrosen · New York University School Of Medicine · UG1 · FY2019 · DA
HUMAN IMMUNE RESPONSES TO HPV VACCINES
$759,441Johns Hopkins University · P01 · FY2003 · AI
GBS mediated in utero fetal injury
$759,395Lakshmi Rajagopal · Seattle Children'S Hospital · R01 · FY2015 · AI
Vaccine and Treatment Evaluation Units (VTEU)
$759,381Hana M El Sahli · Baylor College Of Medicine · UM1 · FY2022 · AI